Morgan Fox
Political DirectorNORMLMorgan Fox is the Political Director at NORML, focusing on congressional lobbying and changing federal cannabis laws. As a professional cannabis policy reform advocate since 2008, Morgan has been directly involved in dozens of successful state ballot initiative campaigns to establish medical and adult use cannabis programs, as well as legislative victories at the local, state, and federal levels. He has been featured in hundreds of print, radio, television, and online publications. Morgan was most recently the Media Relations Director and chief spokesperson for the National Cannabis Industry Association (NCIA) before joining NORML, and spent nearly a decade at the Marijuana Policy Project (MPP) prior to that. He lives in Washington, DC, and when he’s not working to end prohibition and repair the damage it has caused, he can usually be found exploring the numerous parks and playgrounds of our nation’s capital with his children.
Solving for Schedule III: What Rescheduling Means for Operators
Rescheduling has sparked more questions than answers, and operators are making decisions in a fog of speculation. This session cuts through the noise
Rescheduling has sparked more questions than answers, and operators are making decisions in a fog of speculation. This session cuts through the noise with a clear-eyed look at what a move to Schedule III genuinely changes for cannabis businesses, an
Rescheduling has sparked more questions than answers, and operators are making decisions in a fog of speculation. This session cuts through the noise with a clear-eyed look at what a move to Schedule III genuinely changes for cannabis businesses, and what stays the same.
The panelists will unpack the regulatory issues that hit your bottom line. They'll examine Section 280E tax implications, shifting banking access, DEA oversight, and FDA comp
Rescheduling has sparked more questions than answers, and operators are making decisions in a fog of speculation. This session cuts through the noise with a clear-eyed look at what a move to Schedule III genuinely changes for cannabis businesses, and what stays the same.
The panelists will unpack the regulatory issues that hit your bottom line. They'll examine Section 280E tax implications, shifting banking access, DEA oversight, and FDA compliance requirements, with an honest assessment of timelines and open questions. Rather than chase headlines, the panelists will focus on the practical realities shaping cannabis market trends and the opportunities ahead.
